东方生物 (688298.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.9x

Market Cap

CNY 3.77B

MomentumView details →

1D Return

−3.71%

YTD Return

—

RSI (14)

45.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.9x

Market Cap

CNY 3.77B

RSI (14)

45.7

MomentumView details →

1D Return

−3.71%

YTD Return

—

ProfitabilityView details →

Gross Margin

43.88%

Net Margin

−54.56%

EBITDA Margin

−37.51%

ROE (TTM)

−9.37%

ROA (TTM)

−8.01%

Asset Turnover

0.14x

GrowthView details →

Revenue YoY

+20.88%

EPS YoY

+1.34%

FCF YoY

+55.40%

Revenue CAGR 3Y

−52.37%

EPS CAGR 3Y

−10.78%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

3.79x

Quick Ratio

3.42x

Div Yield

—

Div Rate

—

Div Growth 1Y

−67.64%

Financials snapshotView financials →

Revenue (TTM)

1.01B

Net Income (TTM)

−551.99M

Op. CF (TTM)

−168.72M

Latest newsMore news →

OriGene Biotech and its wholly-owned subsidiary Shanghai Wanzijian Bio recently obtained multiple medical device registration certificates in China and overseas, covering syphilis antibody detection, HPV nucleic acid typing, and thyroid-stimulating hormone detection products.2d ago

OriGene Biotech reported a net loss of 222 million yuan for the first half of 2026, compared with a loss of 163 million yuan in the same period of 2025.8d ago

Similar companies

安旭生物688075.SH 健麾信息605186.SH Jenscare Scientific Co., Ltd.09877.HK 祥生医疗688358.SH 普门科技688389.SH Ekso Bionics Holdings, Inc. Common StockCHRN Find similar companies →

Latest newsMore news →

OriGene Biotech and its wholly-owned subsidiary Shanghai Wanzijian Bio recently obtained multiple medical device registration certificates in China and overseas, covering syphilis antibody detection, HPV nucleic acid typing, and thyroid-stimulating hormone detection products.2d ago OriGene Biotech reported a net loss of 222 million yuan for the first half of 2026, compared with a loss of 163 million yuan in the same period of 2025.8d ago